
K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval the exception.

K2 Therapeutics CEO Ying Huang on the drug development pipeline — and the compounding attrition rates that make FDA approval the exception.

Hanmi Pharm licenses its obesity drug candidate HM17321 to Genentech, James LaValle weighs in after FDA advisors back most nominated peptides for the compounding bulks list, and Ivo Carre examines how tau- and microglia-targeted therapies are reshaping the Alzheimer's pipeline beyond amyloid.

Hanmi Pharm has licensed HM17321 to Genentech for up to $2.3 billion, including a $190 million upfront payment.

In the first part of a two-part series, Carre reviews of the tau and TREM2 approaches reshaping Alzheimer's drug development, with key findings from AAIC 2026 in London.

K2 Therapeutics CEO Ying Huang on how in-licensing assets with existing human data can cut years and billions from the drug development timeline.

James LaValle, chair of the International Peptide Society, notes how the advisory committee's favorable vote on peptides for the 503A Bulks List was a meaningful step without constituting approval.

Amplitude Therapeutics and Chai Discovery ink AI and RNA collaborations with Eli Lilly and Bristol Myers Squibb, Norstella's Dan Chancellor makes the case for dealmaking as a survival skill, and this week's rare disease approvals and a $322 million biosimilar deal reveal where pharma strategy is heading.

From an approval for a disease affecting 900 people worldwide to a new drug class in multiple myeloma and a $322 million biosimilar collaboration — this week's deals and approvals reveal a lot about how pharmaceutical strategy is evolving.

Amplitude Therapeutics enters a collaboration with Eli Lilly to develop trans-amplifying RNA vaccines, while Chai Discovery partners with Bristol Myers Squibb to deploy its AI molecular folding and design models across BMS's antibody discovery portfolio.

K2 Therapeutics CEO Ying Huang discusses why government investment and US-trained returnees have made China's biotech innovation surge irreversible.

Norstella’s VP of thought leadership discusses why pharma spent more on R&D, got fewer drugs, and is heading toward a $500 billion patent cliff unprepared.

A partnership roundup covers deals from IntraGel Therapeutics/UroGen Pharma and Lupin/Tenpoint Therapeutics, FDA approves Regeneron's Pasatru for fibrodysplasia ossificans progressiva, and RELEX's Rohit Tripathi discusses reshoring pharma manufacturing.

UroGen Pharma has invested in IntraGel Therapeutics and secured an exclusive option to license Tumocure, and Lupin's subsidiary has licensed European commercialization rights to Tenpoint's Yuvezzi.

FDA has approved Regeneron's Pasatru ,the first treatment for fibrodysplasia ossificans progressiva in adults.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks with Pharmaceutical Executive about the impact new phased tariffs will have on reshoring pharma manufacturing.

In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI surfaces is.

President Trump moves to nominate Heidi Overton as FDA commissioner, Ron Lanton weighs in on drug pricing's collision with trade policy, and Mohd Haque looks at how pharma leaders are scaling AI across the drug lifecycle.

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner.

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy is producing structural change.

LEO Pharma, BioMarin, OmniAb, and Chugai post a busy week of pharma dealmaking, RELEX's Rohit Tripathi weighs in on who ultimately pays for tariff-driven input costs, and Spherix Global Insights' Sybil Mead unpacks IRA-driven formulary pressure spreading across payer portfolios.

LEO Pharma agrees to acquire dersimelagon, OmniAb signs a ion channel discovery collaboration with Eli Lilly, Chugai grants GSK an exclusive worldwide license to AID351, and BioMarin acquires Alesta Therapeutics to gain ALE1.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks about who will actually pay for the phased tariff-driven cost increases.

Spherix's VP of market access discusses how the IRA's maximum fair price is reshaping payer strategy, formulary design, and patient out-of-pocket costs far beyond negotiated drugs.

Henlius and Sandoz ink a biosimilars collaboration, ADVI's Tyler Seville makes the case for 340B reform, and RELEX's Rohit Tripathi weighs in on what real pharma reshoring requires.

Henlius Biotech has granted Sandoz exclusive ex-China commercialization rights to up to 10 monoclonal antibody and ADC biosimilars for up to $322 million.

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.

ADVI’s associate director of market access policy strategy discusses how 340B grew to $100 billion, lost its safety-net purpose, and became a compliance nightmare when the IRA arrived.

From a $1.32 billion rare epilepsy acquisition to AI drug discovery partnerships, biotech IPOs, and a rare disease investment rebound — here's what moved the market this week.